Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review

References

• Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res. 2009;130:311–21. PMID:19901440.
   PubMed Web of Science ®Google Scholar
• Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 2007;7:11–22. doi:10.1038/nrc2050. PMID:17186016.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin H-R, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi:10.1016/S1470-2045(10)70230-8. PMID:20952254.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1–16. doi:10.1016/j.vaccine.2008.05.064.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S3/11–25.
   PubMedGoogle Scholar
• McGraw SL, Ferrante JM. Update on prevention and screening of cervical cancer. World J Clin Oncol. 2014;5:744–52. doi:10.5306/wjco.v5.i4.744. PMID:25302174.
   PubMedGoogle Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180–4. doi:10.1073/pnas.89.24.12180. PMID:1334560.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. doi:10.1056/NEJMoa061741. PMID:17494925.
   PubMed Web of Science ®Google Scholar
• Approved Products >Cervarix [Internet]. [cited 2017 Sep 20]; Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm
   Google Scholar
• Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol. 2015;16:e56. doi:10.1016/S1470-2045(14)71191-X. PMID:25532625.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE, Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4. PMID:25811679
   PubMed Web of Science ®Google Scholar
• Meites E. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep [Internet] 2016 [cited 2017 Sep 20]; 65. Available from: https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm
   Google Scholar
• Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2014;18:651–9.
   PubMed Web of Science ®Google Scholar
• Research C for BE and. Approved Products – Gardasil [Internet]. [cited 2017 Dec 1]; Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm
   Google Scholar
• Research C for BE and. Approved Products – Gardasil 9 [Internet]. [cited 2017 Dec 1]; Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm
   Google Scholar
• WHO | Global Advisory Committee on Vaccine Safety,<br>7–8 June 2017 [Internet]. WHO [cited 2017 Dec 1]; Available from: http://www.who.int/vaccine_safety/committee/reports/June_2017/en/
   Google Scholar
• Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giraldo PC, Gonçalves AK. Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials. J Immunol Res. 2017;2017:3736201. doi:10.1155/2017/3736201. PMID:28812030.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2008;18:1013–9.
   Google Scholar
• Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, et al. Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. Arch Pediatr Adolesc Med 2012; 166:1140. doi:10.1001/archpediatrics.2012.1451. PMID:23027469.
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: A case–control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res. 2017;65:46–54. doi:10.1007/s12026-016-8815-9. PMID:27406735.
   PubMed Web of Science ®Google Scholar
• Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209. doi:10.1016/j.phrs.2015.08.003. PMID:26275795.
   PubMed Web of Science ®Google Scholar
• Siegrist C-A. Autoimmune diseases after adolescent or adult immunization: What should we expect?. CMAJ Can Med Assoc J J Assoc Medicale Can. 2007;177:1352–4. doi:10.1503/cmaj.071134.
   PubMed Web of Science ®Google Scholar
• Agorastos T, Chatzigeorgiou K, Brotherton JML, Garland SM. Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. Vaccine. 2009;27:7270–81. doi:10.1016/j.vaccine.2009.09.097. PMID:19799849.
   PubMed Web of Science ®Google Scholar
• Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler Houndmills Basingstoke Engl. 2009;15:116–9. doi:10.1177/1352458508096868.
   PubMed Web of Science ®Google Scholar
• WHO | Global Advisory Committee on Vaccine Safety, report of meeting held 12–13 June 2013 [Internet]. WHO [cited 2017 Nov 14]; Available from: http://www.who.int/vaccine_safety/committee/reports/Jun_2013/en/
   Google Scholar
• Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016;138(2). pii: e20154387. doi:10.1542/peds.2015-4387. PMID:27422279
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou P-Y, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:398–408. doi:10.1111/joim.12155. PMID:24206418.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313:54–61. doi:10.1001/jama.2014.16946. PMID:25562266.
   PubMed Web of Science ®Google Scholar
• Willame C, Rosillon D, Zima J, Angelo M-G, Stuurman AL, Vroling H, Boggon R, Bunge EM, Pladevall-Vila M, Baril L. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccines Immunother. 2016;12:2862–71. doi:10.1080/21645515.2016.1199308.
   PubMed Web of Science ®Google Scholar
• Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193–203. doi:10.1111/j.1365-2796.2011.02467.x. PMID:21973261.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71:1506–13. doi:10.1001/jamaneurol.2014.2633. PMID:25329096.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2017 Mar 27]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccines Immunother. 2016;12:1406–17. doi:10.1080/21645515.2016.1168952.
   PubMed Web of Science ®Google Scholar
• Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34:983–91. doi:10.1097/INF.0000000000000793. PMID:26107345.
   PubMed Web of Science ®Google Scholar
• Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol. 2015;73:759-767; quiz 767–768. doi:10.1016/j.jaad.2015.05.041.
   Web of Science ®Google Scholar
• Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13:215–24. doi:10.1016/j.autrev.2013.10.003. PMID:24514081.
   PubMed Web of Science ®Google Scholar
• Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19:1466–87. PMID:23016780
   PubMed Web of Science ®Google Scholar
• Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010;9:90–7. PMID:20193633
   PubMed Web of Science ®Google Scholar
• Macartney KK, Chiu C, Georgousakis M, Brotherton JML. Safety of human papillomavirus vaccines: A review. Drug Saf. 2013;36:393–412. doi:10.1007/s40264-013-0039-5. PMID:23637071.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, Gentili M, Brusadelli T, Clementi E, Radice S. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41. doi:10.1016/j.autrev.2014.01.054. PMID:24468416.
   PubMed Web of Science ®Google Scholar
• Angelo M-G, David M-P, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 2014;23:466–79. doi:10.1002/pds.3554. PMID:24644063.
   PubMed Web of Science ®Google Scholar
• Münz C, Lünemann JD, Getts MT, Miller SD. Antiviral immune responses: Triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009;9:246–58. doi:10.1038/nri2527. PMID:19319143.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination [Internet]. [cited 2017 Mar 12]; Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf?ua=1
   Google Scholar
• Siegrist C-A, Lewis EM, Eskola J, Evans SJW, Black SB. Human papilloma virus immunization in adolescent and young adults: A cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26:979–84. doi:10.1097/INF.0b013e318149dfea. PMID:17984802.
   PubMed Web of Science ®Google Scholar
• Callréus T, Svanström H, Nielsen NM, Poulsen S, Valentiner-Branth P, Hviid A. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Vaccine. 2009;27:2954–8. doi:10.1016/j.vaccine.2009.02.106. PMID:19428906.
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906. doi:10.1136/bmj.f5906. PMID:24108159.
   PubMed Web of Science ®Google Scholar
• HPV Vaccine Administration | Human Papillomavirus Vaccination | CDC [Internet]. [cited 2017 Mar 27]; Available from: https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html
   Google Scholar
• Shaygannejad V, Rezaie N, Paknahad Z, Ashtari F, Maghzi H. The environmental risk factors in multiple sclerosis susceptibility: A case-control study. Adv Biomed Res. 2016;5:98. doi:10.4103/2277-9175.183665. PMID:27376037.
   PubMedGoogle Scholar
• Manouchehrinia A, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, Ban M, Glaser A, Sawcer S, Tremlett H, et al. Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Mult Scler. 2017;23(14):1938–1946. doi:10.1177/1352458517690618.
   PubMed Web of Science ®Google Scholar
• WHO | Human papillomavirus vaccines safety (HPV) [Internet]. WHO [cited 2017 Apr 12]; Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/dec_2013/en/
   Google Scholar
• Buljevac D, Flach HZ, Hop WCJ, Hijdra D, Laman JD, Savelkoul HFJ, van Der Meché FGA, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain J Neurol. 2002;125:952–60. doi:10.1093/brain/awf098.
   Google Scholar
• Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2008;28:17–28. doi:10.1055/s-2007-1019126. PMID:18256984.
   PubMed Web of Science ®Google Scholar
• Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol [Internet] 2007 [cited 2017 Mar 27]; 7. Available from: http://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-7-10 doi:10.1186/1471-2288-7-10.
   PubMed Web of Science ®Google Scholar
• La Torre G, Backhaus I, Mannocci A. Rating for narrative reviews: concept and development of the International Narrative Systematic Assessment tool. Senses Sci. 2015;2:31–5.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34. doi:10.1016/j.jclinepi.2009.06.006. PMID:19631507.
   PubMed Web of Science ®Google Scholar